OSMI 1 is a novel inhibitor of O-GlcNAc transferase (OGT).
OSMI-1 (OGT with a small molecule inhibitor) has been used in proximal ligation assay, Sox2 (SRY (sex determining region Y)-Box 2 ) dual luciferase reporter assay, Sox2 ELISA (enzyme linked immunosorbent assay) and other in vivo approaches, to study the O-Linked β-N-acetylglucosamine (O-GlcNAc) mediated regulation of self-renewal genes in cancer. It has also been used to study the Hippo pathway regulation mediated by O-GlcNAc transferase.
ChEBI: OSMI-1 is a sulfonamide resulting from the formal condensation of the sulfonic acid group of 2-oxo-1,2-dihydroquinoline-6-sulfonic acid with the primary amino group of (2R)-2-amino-N-(2-furylmethyl)-2-(2-methoxyphenyl)-N-(2-thienylmethyl)acetamide. OSMI-1 is a cell permeable inhibitor of O-linked beta-N-acetylglucosamine transferase (O-GlcNAc transferase, OGT). It has a role as an EC 2.* (transferase) inhibitor and an EC 2.4.1.255 (protein O-GlcNAc transferase) inhibitor. It is a sulfonamide, a member of quinolines, a member of furans, a member of thiophenes, an aromatic ether and a tertiary carboxamide.
OGT catalyses the attachment of N-acetylglucosamine moieties to a number proteins during post-translational modification. Inhibition of OGT activity might hinder the rate of viral replication in infections such as Herpes simplex viral disease.
